Western Drug Recalls Prostin Injection Due to Sterility Concerns
Western Drug is recalling Prostin Injection due to a lack of assurance of sterility. The recall covers 16 containers distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant risks such as sterility issues in injectable drugs are categorized as Severe.
Plain-English summary
Western Drug Inc. is recalling 16 containers of Prostin Injection (10 mcg/mL, 25 mcg/mL, and 50 mcg/mL) due to a lack of assurance of sterility. The affected product is a prescription medication manufactured by Western Drug Inc. in Springerville, Arizona.
The recall covers all lots of the product. Distribution was nationwide, specifically in Arizona, California, Georgia, New Mexico, South Carolina, South Dakota, Texas, and Utah.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Prostin Injection 10 mcg/mL, 25 mcg/mL, 50 mcg/mL, Rx, Western Drug Inc. 106 E. Main Street, Springerville, Arizona 85938
- Manufacturer
- Western Drug
- Category
- Drug — Injectable Medication
- Hazard
- Affected units
- 16
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots
Distribution
Part of a larger recall action
This product is one of 91 recalled by Western Drug under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 91 products in this recall →Related recalls
Same manufacturer · Western Drug
See all →- SevereWestern Drug Recalls Sodium Hydroxide 10% Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Methylcobalamin Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Benadryl Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls PZI 40 Insulin Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereWestern Drug Recalls Ketorolac Injection Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Green Valley Drugs Progesterone Injection for Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereProstaglandin Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-04-24
- SevereDowning Labs Recalls Pyridoxine Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- HighTirzepatide Injectable Drug Recalled for Sterility Assurance Defect
FDA (Drugs) · 2024-09-11
- SevereFDA Recalls Alprostadil/Procaine Injectable Solution Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereRiverpoint Pharmacy Recalls Prostaglandin Injection Due to Sterility Concerns
FDA (Drugs) · 2019-07-17